Prostaglandin E2 receptors and COX enxymes in human hepatocellular carcinoma: role in the regulation of cell growth

6533b7d8fe1ef96bd126af69

RESEARCH PRODUCT

Prostaglandin E2 receptors and COX enxymes in human hepatocellular carcinoma: role in the regulation of cell growth

Antonina Azzolina Giuseppe Montalto Daniela Foderà Antonella Cusimano Melchiorre Cervello Natale D'alessandro Monica Notarbartolo Nadia Lampiasi Lydia Giannitrapani

subject

Male medicine.medical_specialty EP receptor Settore MED/09 - Medicina Interna Carcinoma Hepatocellular medicine.drug_class Prostaglandin medicine.medical_treatment General Biochemistry Genetics and Molecular Biology hepatocellular carcinoma (HCC)History and Philosophy of Science Internal medicine Cell Line Tumor medicine cell growth Humans Receptors Prostaglandin E Prostaglandin E2 Receptor Aged COX-1 Chemistry Cell growth General Neuroscience Liver Neoplasms COX-2 Middle Aged medicine.disease Receptor antagonist NSAID In vitro Cyclooxygenase Endocrinology Prostaglandin-Endoperoxide Synthases Hepatocellular carcinoma Settore BIO/14 - Farmacologia Cancer research Female Liver cancer Cell Division Prostaglandin E medicine.drug

description

The aim of this study was to investigate the expression of prostaglandin E 2 receptors (EP 1-4 ), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP 1 receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP 1-4 , COX-1, and COX-2 mRNA expression was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP 1 receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP 1 receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP 1 receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP 1 antagonists and COX inhibitors in the treatment of liver cancer.

year	journal	country	edition	language
2008-01-01

http://hdl.handle.net/10447/37533